{"id":104464,"date":"2026-04-13T06:57:24","date_gmt":"2026-04-13T04:57:24","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=104464"},"modified":"2026-04-13T06:57:24","modified_gmt":"2026-04-13T04:57:24","slug":"80-pacientu-hlasi-zlepseni-nebo-stabilizaci-rakoviny-po-6-mesicich-lecby-ivermektinem-a-mebendazolem","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2026\/04\/13\/80-pacientu-hlasi-zlepseni-nebo-stabilizaci-rakoviny-po-6-mesicich-lecby-ivermektinem-a-mebendazolem\/","title":{"rendered":"80% pacient\u016f hl\u00e1s\u00ed zlep\u0161en\u00ed nebo stabilizaci rakoviny po 6 m\u011bs\u00edc\u00edch l\u00e9\u010dby ivermektinem a mebendazolem"},"content":{"rendered":"<div id=\"fb-root\"><\/div>\n<p><strong><span dir=\"auto\">Dokon\u010dili jsme dosud nejv\u011bt\u0161\u00ed anal\u00fdzu na lidech v re\u00e1ln\u00e9m sv\u011bt\u011b, kter\u00e1 hodnot\u00ed\u00a0<\/span><a href=\"https:\/\/www.badatel.net\/podla-novej-studie-ivermektin-zmensuje-nadory-na-mozgu-az-o-70\/\"><span dir=\"auto\">ivermektin<\/span><\/a><span dir=\"auto\">\u00a0a mebendazol u pacient\u016f s rakovinou.<\/span><\/strong><\/p>\n<p><span dir=\"auto\">No a v\u00fdsledky p\u0159edstavuj\u00ed jeden z nejp\u0159esv\u011bd\u010div\u011bj\u0161\u00edch klinick\u00fdch sign\u00e1l\u016f, jak\u00e9 byly kdy zdokumentov\u00e1ny pro antiparazit\u00e1rn\u00ed terapie v onkologii.<\/span><\/p>\n<p><span dir=\"auto\">Rukopis je nyn\u00ed k dispozici jako p\u0159edtisk na v\u00fdzkumn\u00e9m repozit\u00e1\u0159i\u00a0<\/span><a href=\"https:\/\/zenodo.org\/records\/19455636\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">Zenodo<\/span><\/a><span dir=\"auto\">\u00a0, kter\u00fd provozuje\u00a0<\/span><em><span dir=\"auto\">Evropsk\u00e1 organizace pro jadern\u00fd v\u00fdzkum<\/span><\/em><span dir=\"auto\">\u00a0, a z\u00e1rove\u0148 proch\u00e1z\u00ed recenzn\u00edm jedn\u00e1n\u00edm v p\u0159edn\u00edch onkologick\u00fdch \u010dasopisech pod n\u00e1zvem \u201eRe\u00e1ln\u00e9 klinick\u00e9 v\u00fdsledky l\u00e9\u010dby ivermektinu a mebendazolu u pacient\u016f s rakovinou: V\u00fdsledky prospektivn\u00ed observa\u010dn\u00ed kohorty\u201c.<\/span><\/p>\n<p><span dir=\"auto\">V tomto hodnocen\u00ed prospektivn\u00edho klinick\u00e9ho programu z re\u00e1ln\u00e9ho sv\u011bta byla r\u016fznorod\u00e9 populaci pacient\u016f s rakovinou p\u0159edeps\u00e1na kombinace ivermektinu a mebendazolu, p\u0159i\u010dem\u017e ka\u017ed\u00e1 tobolka obsahovala 25 mg ivermektinu a 250 mg mebendazolu.<\/span><\/p>\n<p><span dir=\"auto\">P\u0159ibli\u017en\u011b \u0161est m\u011bs\u00edc\u016f po zah\u00e1jen\u00ed l\u00e9\u010dby jsme pozorovali pom\u011br klinick\u00e9ho p\u0159\u00ednosu 84,4%, p\u0159i\u010dem\u017e t\u00e9m\u011b\u0159 polovina pacient\u016f s rakovinou (48,4%) neuv\u00e1d\u011bla bu\u010f \u017e\u00e1dn\u00e9 zn\u00e1mky onemocn\u011bn\u00ed (32,8%), nebo regresi n\u00e1doru (15,6%). Dal\u0161\u00edch 36,1% uvedlo stabilizaci onemocn\u011bn\u00ed.<\/span><\/p>\n<p><span dir=\"auto\">To znamen\u00e1, \u017ee v\u00edce ne\u017e \u010dty\u0159i z p\u011bti pacient\u016f uvedli bu\u010f zlep\u0161en\u00ed, nebo stabilizaci sv\u00e9ho rakovinov\u00e9ho stavu.<\/span><\/p>\n<p><span dir=\"auto\">Tyto v\u00fdsledky nazna\u010duj\u00ed, \u017ee levn\u00e9 a bezpe\u010dn\u00e9 aplikace zm\u00edn\u011bn\u00fdch generick\u00fdch l\u00e9k\u016f mimo schv\u00e1len\u00e9 indikace by mohly b\u00fdt d\u016fle\u017eit\u00fdm dopl\u0148kem p\u0159i l\u00e9\u010db\u011b rakoviny.<\/span><\/p>\n<p><span dir=\"auto\">Pr\u016flomov\u00e1 anal\u00fdza byla mo\u017en\u00e1 d\u00edky jedine\u010dn\u00e9 spolupr\u00e1ci mezi spole\u010dnost\u00ed\u00a0<\/span><em><span dir=\"auto\">The Wellness Company<\/span><\/em><span dir=\"auto\">\u00a0, nadac\u00ed\u00a0<\/span><em><span dir=\"auto\">McCullough Foundation<\/span><\/em><span dir=\"auto\">\u00a0a p\u0159edsedou prezidentsk\u00e9ho panelu pro rakovinu. Anal\u00fdza spojila klinick\u00e9 \u00fadaje z re\u00e1ln\u00e9ho sv\u011bta, zku\u0161enosti z prvn\u00ed linie a vysoko\u00farov\u0148ov\u00e9 epidemiologick\u00e9 znalosti s c\u00edlem poskytnout nal\u00e9hav\u011b pot\u0159ebn\u00e9 poznatky v onkologii.<\/span><\/p>\n<p><span dir=\"auto\">Uvedenou pr\u00e1ci vykonali: Nicolas Hulscher, MPH (j\u00e1); Kelly Victory, MD (pozn. redakce: MD = l\u00e9ka\u0159 medic\u00edny jako u n\u00e1s MUDr.); James A. Thorp, MD; Drew Pinsky, MD; Alejandro Diaz-Villalobos, MD; Peter Gillooly, MSc; Foster Coulson; Melissa Annazone; Chloe Radesi; Jessica Brooks; Peter A. McCullough, MD, MPH; a Harvey Risch, MD, PhD (p\u0159edseda prezidentsk\u00e9ho panelu pro rakovinu).<\/span><\/p>\n<p><span dir=\"auto\">Dokument je dostupn\u00fd\u00a0<\/span><a href=\"https:\/\/zenodo.org\/records\/19455636\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">ZDE<\/span><\/a><span dir=\"auto\">\u00a0.<\/span><\/p>\n<h2><span dir=\"auto\">Jak prob\u011bhla anal\u00fdza a sb\u011br dat<\/span><\/h2>\n<p><span dir=\"auto\">Analyzovali jsme prospektivn\u00ed observa\u010dn\u00ed kohortu 197 pacient\u016f s rakovinou, p\u0159i\u010dem\u017e 122 z nich dokon\u010dilo strukturovan\u00e9 sledov\u00e1n\u00ed p\u0159ibli\u017en\u011b po \u0161esti m\u011bs\u00edc\u00edch (m\u00edra odpov\u011bdi 61,9%).<\/span><\/p>\n<p><span dir=\"auto\">Pacient\u016fm byl licencovan\u00fdmi poskytovateli v USA p\u0159edeps\u00e1n kombinovan\u00fd protokol ivermektinu a mebendazolu a v\u00fdsledky byly shrom\u00e1\u017ed\u011bny prost\u0159ednictv\u00edm standardizovan\u00fdch digit\u00e1ln\u00edch pr\u016fzkum\u016f hodnot\u00edc\u00edch stav rakoviny, dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby a bezpe\u010dnost.<\/span><\/p>\n<p><span dir=\"auto\">Jedna tobolka obsahovala 25 mg ivermektinu a 250 mg mebendazolu, p\u0159i\u010dem\u017e d\u00e1vkov\u00e1n\u00ed bylo individu\u00e1ln\u011b stanoveno l\u00e9ka\u0159i (nej\u010dast\u011bji 1 a\u017e 2 tobolky denn\u011b), a\u010dkoli podskupina pacient\u016f pou\u017e\u00edvala vy\u0161\u0161\u00ed denn\u00ed d\u00e1vkov\u00e1n\u00ed nebo cyklick\u00e9 re\u017eimy v z\u00e1vislosti na stavu onemocn\u011bn\u00ed a tolerance.<\/span><\/p>\n<p><span dir=\"auto\">D\u016fle\u017eit\u00e9 je, \u017ee \u0161lo o prospektivn\u00ed, tedy strukturovan\u00e9 hodnocen\u00ed klinick\u00e9ho programu, kter\u00e9 zachycovalo v\u00fdsledky po del\u0161\u00ed dobu hl\u00e1\u0161en\u00e9 pacienty, a ne jen retrospektivn\u00ed zp\u011btn\u00e9 vazby, \u010d\u00edm\u017e se pos\u00edlila vnit\u0159n\u00ed konzistentnost zji\u0161t\u011bn\u00ed.<\/span><\/p>\n<h2><span dir=\"auto\">Populace pacient\u016f: Pokro\u010dil\u00e1, rozmanit\u00e1 a klinicky relevantn\u00ed<\/span><\/h2>\n<p><span dir=\"auto\">Na\u0161e kohorta p\u0159edstavovala \u0161irok\u00fd a klinicky v\u00fdznamn\u00fd pr\u016f\u0159ez pacient\u016f s rakovinou, v\u010detn\u011b pacient\u016f s rakovinou prostaty (27,9%), prsu (18,3%), plic (8,6%), tlust\u00e9ho st\u0159eva (5,1%) a \u0161irok\u00e9 \u0161k\u00e1ly dal\u0161\u00edch malignit.<\/span><\/p>\n<p><span dir=\"auto\">Ne\u0161lo o populaci omezenou na onemocn\u011bn\u00ed v ran\u00e9m st\u00e1diu nebo s n\u00edzk\u00fdm rizikem. Pr\u016f\u0159ez byl n\u00e1sleduj\u00edc\u00ed:<\/span><\/p>\n<ul>\n<li><span dir=\"auto\">Aktivn\u00ed progresivn\u00ed rakovinu hl\u00e1silo 37,1% pacient\u016f.<\/span><\/li>\n<li><span dir=\"auto\">T\u00e9m\u011b\u0159 polovina byla do jednoho roku od stanoven\u00ed diagn\u00f3zy, zat\u00edmco jin\u00ed m\u011bli dlouhodob\u00e9 onemocn\u011bn\u00ed.<\/span><\/li>\n<li><span dir=\"auto\">Mnoz\u00ed ji\u017e podstoupili standardn\u00ed terapie &#8211; chemoterapii (31,5%), oza\u0159ov\u00e1n\u00ed (28,9%), chirurgick\u00fd z\u00e1krok (42,1%).<\/span><\/li>\n<\/ul>\n<p><span dir=\"auto\">Toto odr\u00e1\u017e\u00ed skute\u010dnou onkologickou populaci v\u010detn\u011b pacient\u016f s expozic\u00ed l\u00e9\u010db\u011b, prob\u00edhaj\u00edc\u00ed progres\u00ed a komplexn\u00ed klinickou anamn\u00e9zou.<\/span><\/p>\n<h2><span dir=\"auto\">Prim\u00e1rn\u00ed v\u00fdsledky<\/span><\/h2>\n<p><span dir=\"auto\">P\u0159ibli\u017en\u011b po \u0161esti m\u011bs\u00edc\u00edch bylo dosa\u017eeno t\u011bchto v\u00fdsledk\u016f:<\/span><\/p>\n<ul>\n<li><span dir=\"auto\">\u017e\u00e1dn\u00fd n\u00e1lez onemocn\u011bn\u00ed: 32,8%<\/span><\/li>\n<li><span dir=\"auto\">regrese n\u00e1doru: 15,6%<\/span><\/li>\n<li><span dir=\"auto\">stabilizovan\u00e9 onemocn\u011bn\u00ed: 36,1%<\/span><\/li>\n<li><span dir=\"auto\">progrese: 15,6%<\/span><\/li>\n<\/ul>\n<p><span dir=\"auto\">To vede k pom\u011bru klinick\u00e9ho p\u0159\u00ednosu 84,4%, co\u017e znamen\u00e1, \u017ee v\u00edce ne\u017e \u010dty\u0159i z p\u011bti pacient\u016f hl\u00e1sili bu\u010f zlep\u0161en\u00ed, nebo stabilizaci sv\u00e9ho rakovinov\u00e9ho onemocn\u011bn\u00ed.<\/span><\/p>\n<p><span dir=\"auto\">Rozhoduj\u00edc\u00ed je, \u017ee 48,4% m\u00edra \u00fapln\u00e9ho vyl\u00e9\u010den\u00ed + regrese p\u0159edstavuje nejsiln\u011bj\u0161\u00ed sign\u00e1l. To nazna\u010duje, \u017ee podstatn\u00e1 \u010d\u00e1st pacient\u016f se nejen stabilizovala, ale hl\u00e1sila i smyslupln\u00e9 zvr\u00e1cen\u00ed z\u00e1t\u011b\u017ee onemocn\u011bn\u00ed.<\/span><\/p>\n<h2><span dir=\"auto\">Proveditelnost v re\u00e1ln\u00e9m sv\u011bt\u011b<\/span><\/h2>\n<p><span dir=\"auto\">Dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby bylo pozoruhodn\u011b vysok\u00e9:<\/span><\/p>\n<ul>\n<li><span dir=\"auto\">86,9% dokon\u010dilo cel\u00fd po\u010d\u00e1te\u010dn\u00ed protokol s 90 kapslemi<\/span><\/li>\n<li><span dir=\"auto\">66,4% z\u016fstalo na l\u00e9\u010db\u011b \u0161est m\u011bs\u00edc\u016f.<\/span><\/li>\n<\/ul>\n<p><span dir=\"auto\">Tato \u00farove\u0148 dodr\u017eov\u00e1n\u00ed l\u00e9\u010dby je v onkologii neobvykl\u00e1 a nazna\u010duje, \u017ee re\u017eim je pro pacienty tolerovateln\u00fd a p\u0159ijateln\u00fd po del\u0161\u00ed obdob\u00ed.<\/span><\/p>\n<p><span dir=\"auto\">Krom\u011b toho mnoz\u00ed pacienti nad\u00e1le dost\u00e1vali soub\u011b\u017en\u00e9 terapie b\u011bhem n\u00e1sledn\u00e9ho sledov\u00e1n\u00ed, v\u010detn\u011b chemoterapie (27,9%), radioterapie (21,3%) a chirurgick\u00e9ho z\u00e1kroku (19,7%), spolu s u\u017e\u00edv\u00e1n\u00edm dopl\u0148k\u016f v\u00fd\u017eivy (49,2%) a \u00fapravou stravy (37,7%).<\/span><\/p>\n<p><span dir=\"auto\">Pozoruhodn\u00e9 v\u00fdsledky l\u00e9\u010dby rakoviny byly tedy pozorov\u00e1ny v re\u00e1ln\u00fdch klinick\u00fdch podm\u00ednk\u00e1ch, kde jsou pacienti \u010dasto l\u00e9\u010deni multimod\u00e1ln\u00edmi p\u0159\u00edstupy, a nikoli izolovanou monoterapi\u00ed.<\/span><\/p>\n<p><span dir=\"auto\">Konzistentn\u00ed sign\u00e1l o p\u0159\u00ednosu v tomto kontextu podporuje roli ivermektinu a mebendazolu jako dopl\u0148kov\u00fdch terapi\u00ed, kter\u00e9 lze integrovat se standardn\u00ed l\u00e9\u010dbou.<\/span><\/p>\n<h2><span dir=\"auto\">Bezpe\u010dnostn\u00ed profil: N\u00edzk\u00e1 toxicita, vysok\u00e1 m\u00edra konzistentnosti<\/span><\/h2>\n<p><span dir=\"auto\">Bezpe\u010dnostn\u00ed v\u00fdsledky d\u00e1le podporuj\u00ed proveditelnost terapie:<\/span><\/p>\n<ul>\n<li><span dir=\"auto\">25,4% lid\u00ed hl\u00e1silo vedlej\u0161\u00ed \u00fa\u010dinky, p\u0159ev\u00e1\u017en\u011b m\u00edrn\u00e9 (nap\u0159. gastrointestin\u00e1ln\u00ed p\u0159\u00edznaky)<\/span><\/li>\n<li><span dir=\"auto\">93,6% lid\u00ed s vedlej\u0161\u00edmi \u00fa\u010dinky pokra\u010dovalo v l\u00e9\u010db\u011b s men\u0161\u00edmi \u00fapravami<\/span><\/li>\n<\/ul>\n<p><span dir=\"auto\">Toto je v ostr\u00e9m kontrastu s toxickou z\u00e1t\u011b\u017e\u00ed mnoha konven\u010dn\u00edch onkologick\u00fdch terapi\u00ed a podporuje ozna\u010den\u00ed uveden\u00e9ho protokolu jako n\u00edzkotoxick\u00e9ho terapeutick\u00e9ho p\u0159\u00edstupu vhodn\u00e9ho pro dlouhodob\u00e9 pou\u017e\u00edv\u00e1n\u00ed.<\/span><\/p>\n<h2><span dir=\"auto\">Z\u00e1v\u011br<\/span><\/h2>\n<p><span dir=\"auto\">Tato v\u016fbec prvn\u00ed anal\u00fdza protokolu ivermektin-mebendazol u pacient\u016f s rakovinou v re\u00e1ln\u00e9m sv\u011bt\u011b poskytuje p\u0159esv\u011bd\u010div\u00fd sign\u00e1l, kter\u00fd vy\u017eaduje v\u00e1\u017enou pozornost.<\/span><\/p>\n<p><span dir=\"auto\">A\u010dkoli by tato zji\u0161t\u011bn\u00ed m\u011bla b\u00fdt interpretov\u00e1na p\u0159im\u011b\u0159en\u011b jako d\u016fkazy generuj\u00edc\u00ed hypot\u00e9zy z klinick\u00e9ho hodnocen\u00ed v re\u00e1ln\u00e9m sv\u011bt\u011b, rozsah, vnit\u0159n\u00ed konzistence a \u0161irok\u00e9 rozlo\u017een\u00ed pozorovan\u00fdch \u00fa\u010dink\u016f nelze ignorovat.<\/span><\/p>\n<p><span dir=\"auto\">Nepozorujeme margin\u00e1ln\u00ed zm\u011bny ani izolovan\u00e9 reakce \u2013 pozorujeme rozs\u00e1hl\u00e9 zlep\u0161en\u00ed onemocn\u011bn\u00ed hl\u00e1\u0161en\u00e9 samotn\u00fdmi pacienty v r\u016fznorod\u00e9 populaci.<\/span><\/p>\n<p><span dir=\"auto\">Autor: Dr. Nicolas Hulscher, Zdroj:\u00a0<\/span><a href=\"https:\/\/expose-news.com\/2026\/04\/10\/ivermectin-and-mebendazole-treatment-for-cancer\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">expose-news.com<\/span><\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dokon\u010dili jsme dosud nejv\u011bt\u0161\u00ed anal\u00fdzu na lidech v re\u00e1ln\u00e9m sv\u011bt\u011b, kter\u00e1 hodnot\u00ed\u00a0ivermektin\u00a0a mebendazol u pacient\u016f&#8230;<\/p>\n","protected":false},"author":2,"featured_media":104465,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[518,1366,839,21],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/104464"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=104464"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/104464\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/104465"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=104464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=104464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=104464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}